Coronavirus channel feed

Covid-19 roundup: Paul Hud­son says US will have first dibs on Sanofi vac­cine; Gilead se­lects 5 gener­ic man­u­fac­tur­ing part­ners for remde­sivir

5 years ago

FDA is­sues two guid­ances to ac­cel­er­ate Covid-19 treat­ments

5 years ago
FDA+

Covid-19 roundup: The FDA gives Mod­er­na’s Covid-19 team a reg­u­la­to­ry em­brace to go along with the cheers and jeers; BioN­Tech ex­pects first coro­n­avirus da­ta in a mat­ter of weeks

5 years ago

CEPI bets $384M on No­vavax’s Covid-19 vac­cine — cov­er­ing R&D and man­u­fac­tur­ing in the ground­break­ing race to beat the pan­dem­ic

5 years ago
R&D

Covid-19 roundup: Charles Riv­er gets slammed by the pan­dem­ic; For­mer Sanofi R&D chief Elias Zer­houni heads a list of can­di­dates for Covid-19 drug czar; Feds try to sort out remde­sivir dis­tri­b­u­tion mess

6 years ago

More than 1,000 clin­i­cal tri­als were stopped by the pan­dem­ic — in­clud­ing dozens in PhI­II

6 years ago
Bioregnum
R&D

Covid-19 roundup: Can­cer drug re­search takes a big hit, sur­vey finds; Chaot­ic remde­sivir dis­tri­b­u­tion con­tin­ues to anger doc­tors

6 years ago
R&D

Covid-19 roundup: Mod­er­na adds vac­cine ex­perts as PhI­II tri­al looms; Feng Zhang group snags in­stant OK on CRISPR-based test

6 years ago

Flag­ship-backed Evelo Bio­sciences joins Covid-19 hunt with pro­pos­al for bac­te­ria tri­al

6 years ago
R&D

Covid-19 roundup: Epi­demi­ol­o­gist cred­it­ed for shap­ing UK pol­i­cy vi­o­lates lock­down mea­sures; Here's Gilead’s glob­al plan for mass man­u­fac­tur­ing remde­sivir

6 years ago

Covid-19 roundup: Pfiz­er, BioN­Tech start US hu­man tri­al; World lead­ers (not in­clud­ing the US) pledge $8 bil­lion in vac­cine, treat­ment re­search

6 years ago

With the pric­ing ball in Gilead’s court, ICER of­fers some pa­ra­me­ters on how it can be played — an­a­lyst sees at least '$1B in the­o­ry'

6 years ago

Al­ny­lam, Sarep­ta jump in­to Covid-19 game, as pan­dem­ic rekin­dles an­tivi­ral hopes of RNA-tar­get­ing tech­nol­o­gy

6 years ago
R&D
In Focus

FDA cre­ates um­brel­la emer­gency path­way for Covid-19 serol­o­gy tests

6 years ago
FDA+

Covid-19 roundup: Catal­ent signs an­oth­er Covid-19 man­u­fac­tur­ing deal; Eli Lil­ly's an­ti­body part­ner grabs $175M+

6 years ago

FDA cheers on Gilead­'s remde­sivir with a snap emer­gency OK, giv­ing bio­phar­ma a shot at re­demp­tion

6 years ago
R&D
FDA+

Covid-19 roundup: Am­gen toss­es Ote­zla in­to an­ti-in­flam­ma­to­ry mix; Trump thick­ens plot around US probe in­to virus ori­gin

6 years ago

10X: Mod­er­na cre­ates a bil­lion-dose vac­cine pact in a fren­zied race to beat Covid-19 — glob­al­ly

6 years ago
R&D

Af­ter NIH tri­al, EMA be­gins rolling re­view for remde­sivir, set­ting up po­ten­tial au­tho­riza­tions in US and Eu­rope

6 years ago
R&D
FDA+

As­traZeneca vaults to the front of the Covid-19 vac­cine race, team­ing up to glob­al­ize Ox­ford can­di­date

6 years ago
Deals

Covid-19 roundup: GSK CEO Em­ma Walm­s­ley — some tri­al de­lays, but we’re lim­it­ing the dam­age — so far; Trump plan­ning ‘Warp Speed’ vac­cine plan

6 years ago

Da­ta on Gilead­'s an­tivi­ral bring hope for first Covid-19 drug ap­proval

6 years ago
R&D

Gilead — Piv­otal Covid-19 study of remde­sivir ‘met its pri­ma­ry end­point,' is emer­gency au­tho­riza­tion next?

6 years ago
R&D

Full steam ahead, Pfiz­er goes bar­gain hunt­ing in an age of coro­n­avirus — with a spe­cial fo­cus on can­cer and rare dis­eases

6 years ago
Bioregnum
R&D
First page Previous page 51525354555657 Next page Last page
A service from the Financial Times